We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rare Blood Types Due To Genetic Variation

By LabMedica International staff writers
Posted on 15 Mar 2012
Print article
Blood group typing is a routine procedure before blood transfusion, but some blood types, such as Langereis and Junior, are exceedingly rare worldwide.

While blood transfusion problems due to Langereis and Junior blood types are uncommon, several ethnic populations, such as certain Japanese populations and European Gypsies, are at risk.

An international team working with the University of Vermont (Burlington, VT, USA) used a multiplicity of analytical techniques including flow cytometry, immunofluorescence microscopy, mass spectrometry, and sequencing to identify the genetic basis of the Langereis blood group.

The scientists identified the human adenosine triphosphate (ATP)-binding cassette (ABC) transporter ABCB6 as the genetic basis of the Langereis blood group antigen expressed on red blood cells, but also at the plasma membrane of hepatocellular carcinoma (HCC) cells, and established that ABCB6 encodes a new blood group system (Langereis, Lan). Targeted sequencing of ABCB6 in 12 unrelated individuals of the Lan(−) blood type identified 10 different ABCB6 null mutations.

A Lan-specific monoclonal antibody has been developed and will greatly facilitate the identification of Lan(−) blood donors. In elucidating the genetic basis of the Lan(−) blood type, the scientists have uncovered ten null mutations of ABCB6. It will be necessary to closely monitor Lan(−) (ABCB6−/−) individuals, especially those treated with drugs potentially transported by ABCB6, because this deficiency may alter the pharmacokinetics of these drugs or result in adverse effects such as hepatotoxity. The authors concluded that transfusion support of individuals with an anti-Lan antibody is highly challenging partly because of the scarcity of compatible blood donors, but mainly because of the lack of reliable reagents for blood screening

Junior-negative blood donors are extremely rare too, but that may soon change. Bryan Ballif, PhD, an assistant professor at the University of Vermont and an author of the study said, "We're following up on more unknown blood types. There are probably on the order of 10 to 15 more of these unknown blood type systems, where we know there is a problem but we don't know what the protein is that is causing the problem. More than 50,000 Japanese are thought to be Junior negative and may encounter blood transfusion problems or mother-fetus incompatibility."

The study was published in the February 2012 issue of Nature Genetics.

Related Links:

University of Vermont


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
High Performance Centrifuge
CO336/336R
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.